ACOG 2025 Refresh: Menopausal VMS Education in Primary Care

Menopause is often under-recognized and undertreated, JoAnn Pinkerton, MD, told Patient Care in a 2024 interview. Educating women on menopause and available treatment options is important to help increase awareness.

"If physicians ask women about symptoms and listen to what they are experiencing, what they've tried that hasn't worked, and what they've heard or read, and then build a relationship built on trust, that will open the door so you can start to address whether or not they have significant symptoms and what types of therapy they might be a candidate for," said Pinkerton, a professor of obstetrics and gynecology and division director of Midlife Health at the University of Virginia Health System in Charlottesville, Virginia.

Research and analysis of therapies to treatment VMS will be presented and discussed at the 2025 American College of Obstetricians and Gynecologists Annual Clinical & Scientific Meeting, May 16-18, 2025, in Minneapolis, MN. Patient Care will be on the ground with news and expert analysis from the show.

Check out all of our ACOG 2025 coverage.

Pinkerton is also the national lead for the OASIS clinical trial program examining the efficacy and safety of elinzanetant for moderate-to-severe VMS. For details on the OASIS studies, check out part 1 of our interview series: Elinzanetant for Menopausal VMS: OASIS Lead Investigator Discusses Results, Side Effects, Next Steps